Search
Cardiolipin Biosynthesis CL(a-13:0/i-24:0/a-17:0/a-21:0)[rac]
smpdb.ca/view/SMP0493355MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(a-13:0/i-24:0/a-21:0/a-17:0)[rac]
smpdb.ca/view/SMP0493446MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(a-13:0/i-24:0/a-25:0/a-13:0)[rac]
smpdb.ca/view/SMP0493544MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Caplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigationalCaplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker.
Products: CABLIVI®, Cablivi 10 mg/1 mL Enjeksiyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, 1 ADETRosuvastatin
go.drugbank.com/drugs/DB01098ApprovedInvestigationalevents (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks. … as well as the need for surgical revascularization or angioplasty following a heart attack.
Mixtures: ROSUVINA LEGRAND® E 10/40, ROSUVINA LEGRAND® E 10/20Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsCardiolipin Biosynthesis CL(a-13:0/18:2(9Z,11Z)/a-13:0/a-13:0)[rac]
smpdb.ca/view/SMP0351511MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(a-13:0/18:2(9Z,11Z)/a-13:0/a-25:0)[rac]
smpdb.ca/view/SMP0351552MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(a-13:0/18:2(9Z,11Z)/a-15:0/a-21:0)[rac]
smpdb.ca/view/SMP0351649MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(a-13:0/18:2(9Z,11Z)/a-15:0/a-25:0)[rac]
smpdb.ca/view/SMP0351652MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(a-13:0/18:2(9Z,11Z)/a-17:0/a-13:0)[rac]
smpdb.ca/view/SMP0351846MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.